TAS-102 Ups Overall Survival in Refractory Metastatic CRC

Share this content:
TAS-102 Ups Overall Survival in Refractory Metastatic CRC
TAS-102 Ups Overall Survival in Refractory Metastatic CRC

THURSDAY, May 14, 2015 (HealthDay News) -- For patients with refractory metastatic colorectal cancer, the oral agent TAS-102, that combines trifluridine and tipiracil hydrochloride, is associated with improved overall survival, according to a phase 3 study published in the May 14 issue the New England Journal of Medicine.

Robert J. Mayer, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a double-blind phase 3 trial involving 800 patients with refractory colorectal cancer. Participants were randomized in a 2:1 ratio to receive TAS-102 or placebo.

The researchers found that the median overall survival was 5.3 months with placebo and 7.1 months for TAS-102, and the corresponding hazard ratio for death was 0.68 for the TAS-102 group versus the placebo group (P < 0.001). TAS-102 was associated with clinically significant adverse events, including neutropenia (38 percent), leukopenia (21 percent), and febrile neutropenia (4 percent). One death was reported in relation to TAS-102. The median time to worsening performance status was 5.7 months for TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; P < 0.001).

"TAS-102 was shown to have clinical activity in a large population of Japanese and Western patients with heavily pretreated metastatic colorectal cancer, including those whose disease was refractory to fluorouracil," the authors write.

Several authors disclosed financial ties to pharmaceutical and biotechnology companies, including Taiho Oncology-Taiho Pharmaceuticals, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Actigraphy May Overestimate Sleep in ICU Setting

Actigraphy May Overestimate Sleep in ICU Setting

Wide ranges of sleep quality and quantity with use of actigraphy among critically ill patients in ICU

Mortality for Unintentional Drug Poisonings Up Since 1979

Mortality for Unintentional Drug Poisonings Up Since 1979

Trajectory of overall mortality rate smooth; no exponential trajectories in rates for individual drugs

Most Breast Cancer Diagnoses Given Over the Phone

Most Breast Cancer Diagnoses Given Over the Phone

This represents a reversal, with in-person diagnoses more common before 2006

is free, fast, and customized just for you!




Already a member?

Sign In Now »